HOME >> BIOLOGY >> NEWS
Molecular marker predicts success of breast cancer treatment

A new study demonstrates that the ratio of the expression levels of two genes can be used to accurately predict the clinical outcome of tamoxifen treatment for early stage breast cancer. It is the first method to reliably differentiate between patients who experienced disease-free survival and those at risk for tumor recurrence. The findings also provide new insight into the molecular mechanisms that may contribute to tamoxifen resistance.

Tamoxifen is one of the most widely used therapies for breast cancer. It works by blocking the action of estrogen on breast cancer cells. Estrogen directs the growth of normal breast cells, but can also stimulate the abnormal and unregulated cell growth associated with breast cancer. Unfortunately, nearly 40% of breast cancer patients fail to respond to tamoxifen or eventually become resistant to treatment, and there is no reliable way to predict treatment outcome. Dr. Dennis C. Sgroi from the Pathology Department at Massachusetts General Hospital and Dr. Mark G. Erlander from Arcturus Bioscience, Inc. in Mountain View, California examined the gene expression levels in 60 breast cancers from patients who were treated with tamoxifen after their surgery. Measuring gene expression is a way to examine whether or not a gene is functioning. They discovered that the ratio of the expression levels of two genes, HOXB13 and IL17BR, accurately predicted whether tumors reoccurred after treatment with tamoxifen. The researchers also found that when HOXB13 levels were experimentally elevated in cells from normal breast tissue cultured in the laboratory, the cells showed obvious morphological changes and became more invasive in response to growth signals. "This suggests that HOXB13 may directly contribute to tumor invasion and metastasis," explains Dr. Sgroi.

The researchers conclude that the HOXB13:IL17BR expression ratio may provide an effective molecular marker for identifying breast cancer patients who will be less likely to
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
3-Jun-2004


Page: 1 2

Related biology news :

1. Molecular motor implicated in tissue remodeling
2. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
3. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
4. Molecular staples shape a cancer killer
5. Molecular motor myosin VI moves hand over hand, researchers say
6. Molecular therapeutics advance fight against brain cancer
7. Molecular motor shuttles key protein in response to light
8. Molecular traffic cop directs cellular signals
9. Molecular image of genotoxin reveals how bacteria damage human DNA
10. Molecular mechanism found that may improve ability of stem cells to fight disease
11. Molecular midwives hold clues to the origin of life

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/9/2019)... ... March 08, 2019 , ... Ace Laboratories, Inc. ... resveratrol + ribose hard candy lozenges ( http://www.well-mints.com ). , Well-Mints™ each contain ... hard candy base dusted with powdered sugar. , Well-Mints'™ patented technology delivers resveratrol ...
(Date:3/1/2019)... , ... February 28, 2019 , ... Teresa Krabbe, Ph.D., ... Isar of the Technical University Munich, has been awarded an xCELLigence Research Grant for ... improved oncolytic virus platform. , Oncolytic viruses represent an exciting new aspect ...
(Date:2/22/2019)... ... February 20, 2019 , ... RoosterBio, Inc, a privately held ... footprint in Frederick, MD after a year of rapid growth. , “Hundreds of ... cell (hMSCs) products to streamline their product development efforts in the regenerative medicine ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... Calif. (PRWEB) , ... March 19, 2019 , ... Bogey was nine years old when ... arthritis in his left hip. These ailments caused Bogey to experience problems with his ... vehicles, up stairs, and onto his special spot on the couch. , His owners, devastated ...
(Date:3/19/2019)... ... March 19, 2019 , ... ... hospital in Israel and the Middle East region, and Swiss-based CDMO Lonza ... manufacturing platform. The partnership will enable Sheba to vastly streamline its in-house ...
(Date:3/15/2019)... ... March 15, 2019 , ... ... Inc. and affiliate companies including AVAPCO LLC and API Intellectual Properties Holdings. ... Biorefinery and R&D center in Thomaston, Georgia, operations, research, and business development ...
(Date:3/14/2019)... , ... March 14, 2019 , ... ... Conference & Expo, themed “Navigating the Full Spectrum of Case Management,” continues as ... 10-14, 2019. This conference is the only case management industry conference serving the ...
Breaking Biology Technology:
Cached News: